

AMENDMENTS TO THE SPECIFICATION

Amend the paragraph beginning at page 18, line 20, of the WO2004/062684 publication as follows.

Yet another aspect of the present invention relates to the use of stimulators of PACAP signalling in the prevention and treatment of thrombolytic disorders. Examples of stimulators of PACAP signalling include the 38-amino acid form of PACAP (PACAP38), HSDGIFTDSYSRYRKQMAVKKYLA AVL GKRYKQ RVKNK- NH2 (SEQ ID NO:1) and PACAP27, a 27-residue alpha-amidated polypeptide, HSDGIFTDSYSRYRKQMAVKKYLA AVL- NH2 (SEQ ID NO:2), which are both potent agonists of PACAP/VIP receptors. Based on their binding affinity and adenylyl cyclase stimulating properties, PACAP 2-38, PACAP 2-27, AcHIS1 PACAP1-27, Ala2 PACAP (1-27) have also been demonstrated to be potent agonists of PACAP/VIP receptors (Vaudry D. *et al.* cited supra).